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Abstract: Background: Nucleolin (NCL) is a multifunctional protein with oncogenic properties.
Anti-NCL drugs show strong cytotoxic effects, including in triple-negative breast cancer (TNBC)
models, and are currently being evaluated in phase II clinical trials. However, few studies have
investigated the clinical value of NCL and whether NCL stratified cancer patients. Here, we have
investigated for the first time the association of NCL with clinical characteristics in breast cancers
independently of the different subtypes. Methods: Using two independent series (n = 216; n = 661),
we evaluated the prognostic value of NCL in non-metastatic breast cancers using univariate and/or
multivariate Cox-regression analyses. Results: We reported that NCL mRNA expression levels are
markers of poor survivals independently of tumour size and lymph node invasion status (n = 216).
In addition, an association of NCL expression levels with poor survival was observed in TNBC
(n = 40, overall survival (OS) p = 0.0287, disease-free survival (DFS) p = 0.0194). Transcriptomic
analyses issued from The Cancer Genome Atlas (TCGA) database (n = 661) revealed that breast
tumours expressing either low or high NCL mRNA expression levels exhibit different gene expression
profiles. These data suggest that tumours expressing high NCL mRNA levels are different from
those expressing low NCL mRNA levels. Conclusions: NCL is an independent marker of prognosis in
breast cancers. We anticipated that anti-NCL is a promising therapeutic strategy that could rapidly
be evaluated in high NCL-expressing tumours to improve breast cancer management.
Cancers 2018, 10, 390; doi:10.3390/cancers10100390 www.mdpi.com/journal/cancers
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1. Introduction
The expression level of hormonal and growth receptors remains one of the strongest prognostic
biomarkers driving management of breast cancer. The identification of breast cancer subtypes,
which present distinct prognosis associated with particular expression patterns of receptors, has indeed
allowed the development of efficient anti-cancer therapies targeting the differentially expressed
receptors [1]. However, triple-negative breast cancers that exhibit reduced expression of Human
Epidermal Growth Factor Receptor-2 (HER2) and hormonal oestrogen receptor (ER) and progesterone
receptor (PR), are still an on-going challenge since the standard chemotherapy-based treatment has
shown only limited objective response and elevated relapse events. Novel stratification’s markers and
druggable targets are urgently needed for such breast cancer patients.
One opportunity could arise from nucleolin (NCL), a multifunctional protein. NCL is involved
in several molecular processes, including regulation of ribosome biogenesis, transcription by RNA
polymerase II, DNA repair or centrosome formation [2]. NCL is hence involved in numerous biological
functions controlling cellular homeostasis through modulation of cell proliferation, apoptosis, and cell
survival. Recent studies also demonstrated the role of NCL in angiogenesis, epithelial-to-mesenchymal
transition, and stemness [3,4]. In agreement with NCL properties, several in vitro and in vivo studies
had reported an oncogenic effect of NCL that appears to be multifactorial, reflecting its multiple
functions [4].
Several drugs targeting NCL have been developed that specifically induced cell death of tumour
cells [2,5,6]. Among them, two anti-NCL have been evaluated in clinical trials. Since the toxico-kinetic
evaluation of the antagonistic peptide N6L showed accurate results on solid tumours during a
phase I/IIa clinical trial (NCT01711398), a phase II is currently under preparation. In contrast,
the NCL-targeted DNA aptamer AS1411 has shown only limited efficacy in a phase II clinical trial
on unselected patients with advanced stage of renal cell carcinoma: only one patient out of the 35
enrolled ones showed dramatic reduction of tumour burden [7]. Interestingly, most of the anti-NCL
therapies have been evaluated in vitro and in vivo using triple-negative breast cancer models and
showed strong cytotoxic effects, making NCL a powerful candidate for future evaluation of anti-NCL
in breast cancer [6]. Indeed, the antibody 4LB5 inhibiting NCL activity decreased MDA-MB-231 cell
viability, clonogenicity, and tumour growth in xenografts while inducing apoptosis [8]. In addition,
the peptides F3 and HB19 have been shown to significantly reduce tumour growth using MDA-MB-435
and MDA-MB-231 xenografts models, respectively [9,10]. Anti-NCL therapies could thus represent a
novel opportunity for breast cancer, and in particular for triple-negative breast cancer patients.
At present, the role of NCL in cancer is supported only by few studies using human samples
that showed the association of NCL expression with poor overall survival both in solid and liquid
cancers [6,11–13]. In breast cancer, only two studies investigated NCL expression. It has been
reported that NCL is often overexpressed in breast tumours compared to normal tissues and that
NCL overexpression is associated with poor overall survival in HER2-amplified breast cancer [14,15].
Additional studies are required to evaluate more extensively the clinical value of NCL expression in
order to understand the role of NCL in breast cancer.
2. Results
2.1. Association of NCL mRNA Levels with Overall and Disease-Free Survival in Breast Cancer
To evaluate the prognostic value of NCL in non-metastatic breast cancer, we quantified NCL
mRNA expression levels by RT-qPCR in the Dundee series of 216 primary breast tumours (Table 1,
All samples). Since we decided to perform survival association’s study without initial hypothesis
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regarding alteration of NCL in breast tumours, we performed preliminary study to determine a cut-off
based on the distribution of NCL expression. The quartile distribution was first analysed (Figure S1A).
We observed three groups of quartiles (Q2, Q3/Q4, and Q1). We thus used tercile distribution and
confirmed a NCL-based stratification in three groups (Figure S1B). Finally, since we would like to
identify only the true “low” and the true “high”, we thus divided patients in three groups bearing
tumours expressing either low (0–20%), intermediate (20–80%), or high NCL levels (80–100%).
Table 1. Population distribution of Dundee series regarding nucleolin (NCL) expression levels.
Characteristics All Samples(n = 216)
Low NCL
(n = 44)
Intermediate
NCL (n = 129)
High NCL
(n = 43) p-Value
Age
Median 59.0 58.5 59.0 60.0
0.557 #(min–max) (28–90) (28–78) (31–90) (35–88)
Invasive grade
No data 5 2 2 1
Grade 1 14 (6.6%) 0 (0.0%) 8 (6.3%) 6 (14.3%)
0.013 $Grade 2 59 (28.0%) 7 (16.7%) 42 (33.1%) 10 (23.8%)
Grade 3 138 (65.4%) 35 (83.3%) 77 (60.6%) 26 (61.9%)
Tumour size (mm)
n 204 42 120 42
Median 28.0 28.5 28.0 26.0
0.641 #(min–max) (5–110) (11–80) (7–110) (5–110)
Invaded lymph node
No (n = 0) 98 (45.4%) 21 (47.7%) 58 (45.0%) 19 (44.2%)
0.936 †Yes (n ≥ 1) 118 (54.6%) 23 (52.3%) 71 (55.0%) 24 (55.8%)
ER status
No data 2 0 2 0
Negative 70 (32.7%) 25 (56.8%) 34 (26.8%) 11 (25.6%)
<0.001 †Positive 144 (67.3%) 19 (43.2%) 93 (73.2%) 32 (74.4%)
PR status
No data 2 0 2 0
Negative 117 (54.7%) 31 (70.5%) 58 (45.7%) 28 (65.1%)
0.005 †Positive 97 (45.3%) 13 (29.5%) 69 (54.3%) 15 (34.9%)
HER2 status
No data 16 2 11 3
Negative 127 (63.5%) 24 (57.1%) 78 (66.1%) 25 (62.5%)
0.579 †Positive 73 (36.5%) 18 (42.9%) 40 (33.9%) 15 (37.5%)
Intrinsic breast cancer subtype
No data 16 2 11 3
ER+ PR+/− HER2− 87 (43.5%) 11 (26.2%) 58 (49.2%) 18 (45.0%)
0.105 †ER+/− PR+/− HER2+ 73 (36.5%) 18 (42.9%) 40 (33.9%) 15 (37.5%)
ER− PR− HER2− 40 (20.0%) 13 (31.0%) 20 (16.9%) 7 (17.5%)
# Kruskal-Wallis test, $ Fisher exact test, † Chi-2 test. PR: progesterone receptor; ER: oestrogen receptor.
Using Kaplan–Meier survival curves and Log-rank tests, we observed that the expression levels of
NCL were associated to overall and disease-free survivals (Log-rank: overall survival (OS) p = 0.0068;
disease-free survival (DFS) p = 0.0023) (Figure 1A,B). Patients with tumours expressing high NCL
levels had poorer overall and disease-free survival than patients with tumours expressing intermediate
NCL levels. Unexpectedly, we also observed that patients with tumours expressing low NCL levels
had poorer overall and disease-free survivals than patients with tumours expressing intermediate
NCL levels. Similar significant associations were observed with both overall and disease-free
survivals using univariate Cox regression models (p = 0.0083 and p = 0.0030, respectively) (Table S3).
Importantly, the low NCL-expressing group was associated with a higher hazard ratio compared to
the intermediate NCL-expressing group (Low: OS hazard ratio (HR) = 2.13, 95% confidence interval
(95% CI) = (1.30–3.48); DFS HR = 2.20, 95% CI = (1.37–3.52)). A same tendency even if not significant
is observed for the high-versus intermediate NCL-expressing group (High: OS HR = 1.49, 95% CI
95% = (0.90–2.46); DFS HR = 1.60, 95% CI = (1.00–2.58)) (Table S3). However, it has to be noted that
these observations relied on a limited number of samples.
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Figure 1. Association of NCL expression levels with poor prognosis in breast cancer using Dundee
series. A significant association was observed between NCL expression levels and overall (A) as well as
disease-free survivals (B). Association between NCL expression levels and survival was analysed using
Kaplan–Meier representation. Number of su jects at risk is indicated on the graph for the three NCL
groups (low; intermediate; high). Log-rank p-value≤ 0.05 was used to determine significant association.
When compared to 11 healthy mammary tissues, NCL mRNA expression levels of the healthy
donors w re not significantly different from the low L-expressing group, while they were
significantly lower than n the high NCL-expressing groups (Figure S2). It suggests t at high NCL
express on levels correspo ded to NCL overexpression compared to normal tissues (Figure S2).
A second independent series corresponding to a TCGA dataset of 661 primary breast tumours was
used (Table S1). Since the TCGA dataset corresponds to RNA-seq data and Dundee dataset o RT-qPCR
data, we could not compar their expres ion values nor use an absolute cut-off. Thus, cut-off defined
using Dundee series was used for TCGA series. As f r Dundee se ies, a similar tendency was ob erved,
low a d high NCL expr s ion level being associated with poor overall and disea e-free survival (OS
p = 0.1084; DFS p = 0.2658) (Figure S3). The lack of significance could arise from the short follow-up
median of TCGA series (2.81 years; minimum (min): 0; maximum (max): 23.6) compare to the one of
Dundee series (12.4 years; min: 0; max: 17.2) as well s from the difference in clinical characteristics,
such as the variation of tumours proportion in intrinsic breast c ncer subtypes (Tables 1 and S1).
To definitively assess whet er NCL is a prognostic arker in non-metastatic breast cancer, we
performed multivariate Cox regression models using Dundee series on NCL mRNA expression
levels and robust c inical prognostic factors, including tumour size, ly ph node inv ion status
and int insic breast c ncer subtyp s. While the “intrin c breast cancer subtypes” parameter r mained
non-significant, the other pa ameters (NCL, ize, and lymph node invasion) remained in the model.
NCL levels therefore remained associat d with both overall and disease-free survivals ven after
adjustme t on tumour size and lymph node invasion (Table 2). Intere tingly, in overall survival,
NCL al owed for disc iminating the most aggressive breast tumours exhibiting large size t diag osis
(Figure S4). Indeed, this analysis suggests that patients who carry small breast tum urs (<30 mm)
expressing high NCL levels had a poorer overall survival compared to patients w o carry small breast
tumours but expressing i termediate NCL levels for example. NCL thus allow for improving the
current breast cancer patient stratification based n tumour size. These data indicated that NCL mRNA
expression level is an independent marker of prognosis, ev n when compar d to the most robust
clinical pro nostic factors (tumour size and lymph node nvasion status).
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Table 2. Multivariate Cox models in Dundee series.
Variable
Overall Survival Disease-Free Survival
HR 95% CI p-Value HR 95% CI p-Value
NCL
Intermediate 1.00 1.00
Low 2.31 (1.39–3.85) 2.32 (1.43–3.78)
High 1.55 (0.93–2.58) 0.0044 1.67 (1.03–2.71) 0.0019
Tumour size
<30 mm 1.00 1.00
≥30 mm 2.53 (1.66–3.85) <0.0001 2.17 (1.46–3.23) 0.0001
Invaded lymph
nodes
n = 0 1.00 1.00
n ≥ 1 1.60 (1.04–2.46) 0.0320 1.68 (1.12–2.53) 0.0130
HR: hazard ratio; 95% CI: 95% confidence interval.
2.2. Characterization of Breast Tumours Expressing Either Low or High NCL mRNA Levels
Distribution of clinical parameters between the three groups of NCL expression was then
compared to determine whether the breast tumours expressing low or high NCL levels, both associated
with the poorest survivals, shared common traits (Table 1). While mean age, tumour size and invaded
lymph node status at diagnosis showed no significant change in distribution among the three NCL
groups, invasive grade and ER/PR status were significantly different. We noticed that tumours
expressing low levels of NCL mRNA corresponded to 80% to grade 3 tumours, indicative of aggressive
tumours with a high proliferation rate and poorly differentiated. In contrast, tumours expressing
intermediate and high NCL levels corresponded to only 60% to grade 3 tumours. We also observed that
the low NCL-expressing group mainly corresponded to patients carrying ER-negative tumours (about
57% compared to 26% for the intermediate- and high NCL-expressing groups). Finally, both low and
high NCL-expressing groups mainly corresponded to patients with PR-negative tumours compared to
the intermediate-NCL-expressing group (70.5% and 65.1% respectively compared to 46%). From the
clinical point of view, low- and high NCL-expressing breast tumours appeared different.
To further compare tumours expressing low and high NCL levels, we analysed gene expression
profiles in these different tumours. Although survival association with NCL expression was not
significant in TCGA series but nevertheless showed the same tendency than Dundee series, we
used TCGA series for such analysis since the whole transcriptome datasets are available. Clustering
approaches revealed that four out of 10 gene-based clusters exhibited different expression profiles
between tumours expressing low or high NCL levels (Figure S5). Among them, one cluster was
enriched in transcription-related genes, whose expression was higher in tumours expressing high NCL
levels compared to the ones expressing low NCL levels. This was expected knowing the role of NCL
in regulating transcription and proliferation (Cluster 8, Figures S5 and S6, Table S4). Moreover, low
NCL tumours expressed higher levels of genes involved in immunity and cell adhesion compared to
high NCL tumours (Clusters 6 and 7, Figures S5 and S6, Table S4). Overall, these clinical and biological
data suggested that tumours with low and high NCL expression levels corresponded to distinct types
of tumours.
2.3. Prognostic Value of NCL in Breast Cancer Subtypes
Since NCL mRNA expression level was associated with hormonal status, we investigated
whether NCL prognostic value was dependent upon breast cancer subtype. Using Dundee series,
Kaplan–Meier curves were plotted for the three main intrinsic breast cancer subtypes (ER+ PR+/−
HER2− corresponding to the luminal subtype; ER+/− PR+/− HER2+ to a HER2-amplified subtype;
and ER− PR− HER2− to a triple-negative subtype). The affiliation of each tumour to one of the three
NCL-expressing groups (low, intermediate, high) was not re-evaluated for each subtype but conserved
regarding the entire population. No significant association were observed between NCL expression
levels and both overall and disease-free survivals in the ER− PR+/− HER2− and ER+/− PR+/−
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HER2+ breast cancer subtypes (Figure 2A–D). In contrast, a significant association, however based on
a small number of TNBC patients (n = 40), was observed in ER− PR− HER2− breast cancer subtype
(Figure 2E,F). Patients carrying ER− PR− HER2− breast tumours expressing high NCL levels had
poorer overall and disease-free survivals compared to the ones carrying ER− PR− HER2− breast
tumours expressing intermediate NCL levels. A similar tendency was observed for tumours expressing
low NCL mRNA levels. Altogether, these data suggest that NCL could be a prognostic marker in
triple-negative breast cancers.
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were analysed in tumours exhibiting different hormonal status: ER+ PR+/− HER2− (equivalent
to the lu i al s t e, , ); − PR+/− HER2+ (equivalent to the HER2 subtype, C,D); and
ER PR− HER2− (equivalent to the triple-negative subtype, E,F). While NCL expression levels were
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tumours, associations were observed between NCL expression levels and both overall and disease-free
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indicated on the graph for the three NCL groups (low; intermediate; high). Log-rank p-value ≤ 0.05
was used to determine significant association.
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3. Discussion
Although most of studies dedicated to determine the clinical value of NCL have been performed in
neuroepithelial tumours, pancreatic ductal adenocarcinoma (PDAC), hepatocellular carcinoma (HCC),
and leukaemia, few have been performed in breast cancer. Here, we show that NCL expression level is
an independent marker of prognosis in breast cancer. Patients bearing tumours expressing high NCL
mRNA levels, but also unexpectedly the ones expressing low NCL mRNA levels, had poorer overall
and disease-free survivals than other breast cancer patients even when adjusted to two robust clinical
factors, tumour size and lymph node invasion status. Moreover, it appears that tumours expressing
low or high NCL levels corresponded to distinct tumours both from the clinical and biological point
of views.
Up to now and as far as we know, only one study reported an association between NCL expression
and overall survival in breast cancer. Using the TCGA dataset, Wolfson and colleagues showed that
patients carrying HER2-amplified tumours with high NCL expression levels had shorter overall and
disease-free survivals than the ones carrying HER2-amplified tumours with low NCL expression
levels [14]. In our hand, no association was observed in HER2-amplified breast cancers in Dundee
series. This discrepancy could first be explained by difference in clinical characteristics between
Dundee and TCGA series, in particular regarding repartition of intrinsic breast cancer subtypes
(ER+/− PR− HER2+: Dundee 36.5% vs. TCGA 21.8%) (Tables 1 and S1), and choice of cut-off. Second,
HER2 status in TCGA dataset was lacking or uncertain for several patients (about 226, Table S1).
It might thus induce a bias regarding this specific cancer subtype in TCGA series. This is why we
did not use TCGA series to determine whether NCL prognostic value was dependent upon breast
cancer subtype.
A second study reported that NCL expression level was over-expressed in mammary
tumours compared to normal tissues using both immunohistochemistry (IHC) in a panel of eight
normal/tumour pairs and NanoString-quantified mRNA levels in 57 normal vs. 183 triple-negative
breast cancer [15]. A recent review reported similar observations on small series [6]. These data are
concordant with our observation that tumours of the high NCL-expressing group expressed more NCL
mRNA levels than healthy mammary tissues. Interestingly, Pichiorri and colleagues also observed in a
panel of 70 triple-negative breast cancers using IHC that, in addition to the 30% of tumours showing
high NCL staining, NCL was not detected in about 20% of tumours [15]. Although we did not know
why NCL was not detected in this study, this observation nevertheless supported the existence of
tumours with low expression of NCL. We observed that low NCL breast tumours express similar
mRNA levels than normal mastectomy tissues issued from a small cohort (n = 11). From this point
of view, NCL exhibits the same characteristics as ER, PR, and HER2 biomarkers, for which negative
scoring corresponds to expression similar to the that of normal tissue even though they are essential for
clinical stratification of breast cancer. Pichiorri and colleagues did not analyse the survival of patients
carrying mammary tumours expressing these different NCL protein expression levels, thus preventing
comparison with our conclusion on survival association. Due to the limit of our data that only focused
on NCL mRNA level but also on the limited numbers of breast tumour samples, further clinical studies
will be required to analyse correlation of NCL mRNA and protein expression levels in breast tumours.
In particular, additional studies will be required to demonstrate the existence of tumours lacking NCL
expression and the association between low NCL mRNA levels and poor survival.
As observed in our data, it has been reported in a series of 69 stage II PDACs that low level
of nucleoli NCL expression was a marker of poor prognosis independently of age at diagnosis,
tumour size, differentiation, and lymph node invasion status [16]. These data support the association
of low NCL expression levels with poor survival after adjustment with robust prognostic factors,
at least in some cancer types. Indeed, in other cancer types, such as HCC, neuroepithelial cancers,
lung cancers, and acute myeloid leukaemia, high NCL expression levels have been associated with
poor survival [11,12,17,18]. Overall, it suggests that low and high NCL expression levels can be marker
of poor prognosis depending on the biological context. Interestingly, the series used in our study are
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enriched in early breast cancer. Indeed, more than 85% of the breast cancer patients present a tumour
size that is inferior to 50 mm size which is generally used to define early breast cancers. Altogether,
it suggests that low and high NCL expression levels could be a prognostic marker of early breast cancer
able to identify at early stage, patients with poor prognosis.
In vitro and in vivo studies revealed that oncogenic effects of NCL can have multimodal origins
reflecting the multifunctional properties of NCL in the different subcellular compartments [4].
Following this line, it has been reported that decrease of NCL mRNA levels mainly reduced expression
of surface and cytoplasmic NCL protein without affecting the one of nuclear NCL [5], suggesting that
depending on NCL expression levels distinct functions of NCL could be involved. Our data indicated
that mammary tumours expressing low or high NCL levels had different clinical characteristics (i.e.,
tumour grade and ER/PR hormonal status), supporting association with distinct NCL-dependent
functions. Transcriptomic analysis indeed revealed that low NCL tumours expressed high levels
of genes involved in immunity and cell adhesion compared to high NCL tumours. Interestingly,
we recently reported that NCL silencing was associated with an up-regulation of genes involved in
inflammation response in HeLa cells and with increased number of centrosome-like structures in U2OS
cells [19,20].
Overall, our data open up interesting opportunities in clinics. First, several promising anti-NCL
drugs have been developed to fight liquid and solid cancers that are currently evaluated in clinical trials
phase II [2,5–10]. Compared to intermediate and low NCL-expressing tumours, tumours expressing
high NCL are the most prone to respond to anti-NCL drugs. Identifying high NCL-expressing tumours
could thus be viewed as an indispensable companion test for anti-NCL drugs, in particular in TNBC
for which efficient therapy is still lacking. Based on the poor survival rate associated with low
NCL-expressing tumours, one could be afraid that reducing NCL activity in tumours would have
deleterious effects. However, our data suggest that tumours expressing low and high NCL levels
exhibit not reverse but distinct clinical characteristics and gene expression patterns. Thus, we can
expect that inhibition of NCL activity in high NCL-expressing tumours will not promote acquisition
of a “low NCL-expressing tumour”-like phenotype but rather cell death, as reported in numerous
studies. Second, the discovery that NCL is an independent marker of prognosis even after adjustment
on the current gold-standard factors used in clinics for prognosis suggests that NCL could be an
interesting biomarker for treatment decisions. Indeed, one of the remaining issues in breast cancer is
to identify patients that exhibit poor survival even when presenting the “good” prognostic factors at
diagnosis (i.e., small tumour size, no lymph node, or non-TNBC breast cancer subtypes). Such patients
could benefit from treatment protocols usually reserved to more aggressive tumours. In this line,
our multivariate analyses suggest that NCL could be used as a marker to improve treatment decision.
For example, patients with small tumour size at diagnosis exhibit different survival rates depending
on the NCL expression levels (Figure S4). Patients expressing low or high NCL levels showed a poorer
survival rate than the ones expressing intermediate NCL levels, suggesting that the former could
benefit from treatment protocol usually reserved for large tumours. In combination with the current
gold-standard markers, the usage of NCL as biomarker could improve the current patient management.
Moreover, since tumours expressing low NCL levels showed an increased expression in genes involved
in inflammation and immunity, these tumours might benefit from the emerging immuno-therapies.
4. Materials and Methods
4.1. Human Breast Cancer and Healthy Donor Samples
A series of 216 total RNA issued from primary breast tumours were collected at diagnosis from
untreated female patients without metastasis and snap-frozen after macrodissection by a breast cancer
pathologist (Tayside Tissue Bank (TTB), Dundee, Scotland, UK) [21]. Histological tumour grades
and lymph node invasion were determined by breast cancer pathologists (Table 1). Hormonal status
were determined by immunohistochemistry on sections of FFPE tumours [21]. Clinical data were
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collected and maintained by the TTB (last update 2016) that received ethical approval (REC Reference
07/S1402/90). A second series of 661 samples was extracted from the “Breast Invasive Carcinoma
(TCGA, Cell 2015)” dataset of the public database cBioPortal on the basis of the following characteristics:
female patients, primary breast cancer, no metastasis at diagnosis, no family history, no neoadjuvant
treatment, and availability of RNA expression profile (Table S1) [22]. A third series of 11 healthy
mammary tissues obtained from plastic surgery has been collected [23]. This series was approved by
the Bioethic Law No. 2004-800, the Ethic Charter from the French National Institute of Cancer (INCa),
and the ethics committee of Institut Curie.
4.2. RT-qPCR Analyses
RT was carried out using M-MLV Reverse Transcriptase enzyme (Invitrogen, Waltham, MA,
USA). NCL expression levels were quantified by real-time qPCR using BioMark HD System (Fluidigm,
South San Francisco, CA, USA) (Table S2) (See Supplementary Materials and Methods for more
details). Relative fold-changes were calculated using the 2−∆∆CT method, using Human XpressRef
Universal Total RNA (Qiagen, Hilden, Germany) as control sample and GAPDH as housekeeping gene
(Figure S7). Expression levels were measured on two independent sets of triplicates.
4.3. Statistical Analyses
Cut-offs of NCL expression levels were determined using quartile/tercile-based overall survival.
Descriptive statistics were used to summarize patients’ initial characteristics. Between-group
comparisons were performed using a Chi-2’s or Fisher’s exact test for categorical data and t-test
or nonparametric Kruskal–Wallis’ test for continuous data. Overall survival (OS) corresponded to
timing from date of diagnosis to either death or last follow-up for censored patients. Disease-free
survival (DFS) corresponded to timing from date of diagnosis to either relapse, death (if no relapse
had been observed) or last follow-up for censored patients. Survival curves for OS and DFS with
associated log-rank tests were generated using the Kaplan Meier method. Cox proportional hazards
model was used to investigate confounding factors predicting for OS and DFS. In order to adjust
for confounding factors a multivariate Cox models was performed. Variables sufficiently informed
(less than 10% missing value) and significant at a 10% level in univariate analyses were included
in a backward selection procedure to keep factors significant at a 5% level in the final multivariate
model. All p-values corresponded to two-tailed p-values. A p-value ≤ 0.05 was considered statistically
significant. Statistical analyses were performed using either SAS v9.4 (SAS Institute, Cary, NC, USA)
or GraphPad Prism v7.0a softwares (GraphPad Software, Inc., La Jolla, CA, USA).
4.4. Transcriptomic Analyses
In addition to the clinical data and NCL expression extracted from the TCGA database, mRNA
expression z-scores (RNA Seq V2 RSEM) were extracted from database cBioPortal for Cancer Genomics
for the 661 identified breast tumours then divided in the three groups based on NCL expression (low,
intermediate and high). Two-rounds of clustering analyses were performed using k-means clustering
approach (See Supplementary Materials and Methods for additional details). A first clustering was
performed independently in the three groups of NCL expression to identify tumours within the three
NCL-based groups that exhibit similar expression profiles. A second clustering was performed on the
three groups by conserving the previously identified tumour clustering to identify putative difference
in gene expression between the three NCL-based breast tumours. Finally, gene ontology was performed
on gene list issued from each cluster identified in this double k-mean clustering using DAVID tools
(functional annotation clustering) [24].
5. Conclusions
Although breast cancer management has greatly improved in the last decade, a successful
therapeutic strategy is still lacking for some breast cancer patients. In this study, we report that
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NCL is an independent prognostic marker in non-metastatic breast cancers. Our data bring the
first clinical clue that NCL could be not only an useful biomarker to better stratify breast cancer
patients when combined with the current gold-standard biomarkers, but also a promising target for
NCL-overexpressing breast tumours to improve breast cancer management.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/10/10/390/
s1, Figure S1: Cut-off determination for NCL expression using the Dundee series, Figure S2: Comparison of NCL
expression levels in tumours and healthy donors, Figure S3: Association of NCL expression levels with survivals
of breast cancer patients using the TCGA series, Figure S4: Discrimination of the most aggressive breast tumours
with large size at diagnosis using NCL expression, Figure S5: Comparison of gene expression profiles between
the three NCL expressing groups of breast tumours in TCGA series, Figure S6: Gene ontology analysis on the
clusters for which gene expression is different between low and high NCL-expressing breast tumours, Figure S7:
Determination of the most sTable housekeeping gene in our study to normalize RT-qPCR analyses, Table S1:
Characteristics of patients issued from the TCGA dataset, Table S2: Nucelotide sequences of primers used in
the study, Table S3: Univariate Cox regression models for survival in the Dundee series, Table S4: Full gene
ontology analysis.
Author Contributions: Conceptualization, V.M.; Acquisition of data, collection, Analysis and interpretation of
data: L.B.J.; Data curation, F.N.V.L. and S.B.; Formal analysis, A.L.-C.; S.C.; and D.P.; Funding acquisition, P.B.;
J.-J.D. and V.M.; Investigation, F.N.V.L.; Project administration, V.M.; Resources, S.B.; T.D.; A.D.; A.M.T. and J.-C.B.;
Supervision, S.C.; D.P.; J.-J.D.; and V.M.; Visualization, F.N.V.L.; A.L.-C.; and V.M.; Writing–original draft, F.N.V.L.;
J.-J.D. and V.M.; Writing–review and editing, F.N.V.L.; A.L.-C.; S.B.; S.C.; T.D.; A.D.; A.M.T.; J.-C.B.; D.P.; P.B.; J.-J.D.
and V.M.
Funding: This research was funded by PAIR Sein program (ARC_INCa_LNCC_7625), Fondation ARC
(20161204686 and 20171206356) and Ligue Contre le Cancer Comités Allier and Saône-et-Loire (PPE 2016).
F.NVL was a recipient of a fellowship from Ligue Nationale Contre le Cancer (LNCC) and the Fondation pour la
Recherche Médicale (FRM). A.D. and J.-C.B. are supported by Breast Cancer Now fellowship (2012MaySF127).
The Tayside Tissue Bank is supported by the Chief Scientist Office (CSO), NHS, and Dundee University.
Acknowledgments: We thank BioCOS Life Sciences for bioinformatics. We gratefully acknowledge the
contribution to this publication made by the Tayside Tissue Bank (TTB, Dundee, Scotland, UK).
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Cardoso, F.; Harbeck, N.; Barrios, C.H.; Bergh, J.; Cortés, J.; El Saghir, N.; Francis, P.A.; Hudis, C.A.; Ohno, S.;
Partridge, A.H.; et al. Research needs in breast cancer. Ann. Oncol. 2017, 28, 208–217. [CrossRef] [PubMed]
2. Berger, C.M.; Gaume, X.; Bouvet, P. The roles of nucleolin subcellular localization in cancer. Biochimie 2015,
113, 78–85. [CrossRef] [PubMed]
3. Gilles, M.-E.; Maione, F.; Cossutta, M.; Carpentier, G.; Caruana, L.; Di Maria, S.; Houppe, C.; Destouches, D.;
Shchors, K.; Prochasson, C.; et al. Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and
Promotes the Normalization of Tumor Vasculature. Cancer Res. 2016, 76, 7181–7193. [CrossRef] [PubMed]
4. Ugrinova, I.; Petrova, M.; Chalabi-Dchar, M.; Bouvet, P. Multifaceted Nucleolin Protein and Its Molecular
Partners in Oncogenesis. Adv. Protein Chem. Struct. Biol. 2018, 111, 133–164. [PubMed]
5. Hovanessian, A.G.; Soundaramourty, C.; El Khoury, D.; Nondier, I.; Svab, J.; Krust, B. Surface expressed
nucleolin is constantly induced in tumor cells to mediate calcium-dependent ligand internalization.
PLoS ONE 2010, 5, e15787. [CrossRef] [PubMed]
6. Gregório, A.C.; Lacerda, M.; Figueiredo, P.; Simões, S.; Dias, S.; Moreira, J.N. Meeting the needs of breast
cancer: A nucleolin’s perspective. Crit. Rev. Oncol. Hematol. 2018, 125, 89–101. [CrossRef] [PubMed]
7. Rosenberg, J.E.; Bambury, R.M.; Van Allen, E.M.; Drabkin, H.A.; Lara, P.N.; Harzstark, A.L.; Wagle, N.;
Figlin, R.A.; Smith, G.W.; Garraway, L.A.; et al. A phase II trial of AS1411 (a novel nucleolin-targeted DNA
aptamer) in metastatic renal cell carcinoma. Investig. New Drugs 2014, 32, 178–187. [CrossRef] [PubMed]
8. Palmieri, D.; Richmond, T.; Piovan, C.; Sheetz, T.; Zanesi, N.; Troise, F.; James, C.; Wernicke, D.; Nyei, F.;
Gordon, T.J.; et al. Human anti-nucleolin recombinant immunoagent for cancer therapy. Proc. Natl. Acad.
Sci. USA 2015, 112, 9418–9423. [CrossRef] [PubMed]
9. Christian, S.; Pilch, J.; Akerman, M.E.; Porkka, K.; Laakkonen, P.; Ruoslahti, E. Nucleolin expressed at the cell
surface is a marker of endothelial cells in angiogenic blood vessels. J. Cell Biol. 2003, 163, 871–878. [CrossRef]
[PubMed]
Cancers 2018, 10, 390 11 of 11
10. Destouches, D.; El Khoury, D.; Hamma-Kourbali, Y.; Krust, B.; Albanese, P.; Katsoris, P.; Guichard, G.;
Briand, J.P.; Courty, J.; Hovanessian, A.G. Suppression of tumor growth and angiogenesis by a specific
antagonist of the cell-surface expressed nucleolin. PLoS ONE 2008, 3, e2518. [CrossRef] [PubMed]
11. Guo, X.; Xiong, L.; Yu, L.; Li, R.; Wang, Z.; Ren, B.; Dong, J.; Li, B.; Wang, D. Increased level of nucleolin
confers to aggressive tumor progression and poor prognosis in patients with hepatocellular carcinoma after
hepatectomy. Diagn. Pathol. 2014, 9, 175. [CrossRef] [PubMed]
12. Marcel, V.; Catez, F.; Berger, C.M.; Perrial, E.; Plesa, A.; Thomas, X.; Mattei, E.; Hayette, S.; Saintigny, P.;
Bouvet, P.; et al. Expression Profiling of Ribosome Biogenesis Factors Reveals Nucleolin as a Novel Potential
Marker to Predict Outcome in AML Patients. PLoS ONE 2017, 12, e0170160. [CrossRef] [PubMed]
13. Qiu, W.; Zhou, F.; Zhang, Q.; Sun, X.; Shi, X.; Liang, Y.; Wang, X.; Yue, L. Overexpression of nucleolin
and different expression sites both related to the prognosis of gastric cancer. APMIS 2013, 121, 919–925.
[CrossRef] [PubMed]
14. Wolfson, E.; Goldenberg, M.; Solomon, S.; Frishberg, A.; Pinkas-Kramarski, R. Nucleolin-binding by ErbB2
enhances tumorigenicity of ErbB2-positive breast cancer. Oncotarget 2016, 7, 65320–65334. [CrossRef]
[PubMed]
15. Pichiorri, F.; Palmieri, D.; De Luca, L.; Consiglio, J.; You, J.; Rocci, A.; Talabere, T.; Piovan, C.; Lagana, A.;
Cascione, L.; et al. In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.
J. Exp. Med. 2013, 210, 951–968. [CrossRef] [PubMed]
16. Peng, L.; Liang, J.; Wang, H.; Song, X.; Rashid, A.; Gomez, H.F.; Corley, L.J.; Abbruzzese, J.L.; Fleming, J.B.;
Evans, D.B.; et al. High levels of nucleolar expression of nucleolin are associated with better prognosis in
patients with stage II pancreatic ductal adenocarcinoma. Clin. Cancer Res. 2010, 16, 3734–3742. [CrossRef]
[PubMed]
17. Ridley, L.; Rahman, R.; Brundler, M.-A.; Ellison, D.; Lowe, J.; Robson, K.; Prebble, E.; Luckett, I.;
Gilbertson, R.J.; Parkes, S.; et al. Children’s Cancer and Leukaemia Group Biological Studies Committee
Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma. Neuro Oncol. 2008,
10, 675–689. [CrossRef] [PubMed]
18. Zhao, H.; Huang, Y.; Xue, C.; Chen, Y.; Hou, X.; Guo, Y.; Zhao, L.; Hu, Z.H.; Huang, Y.; Luo, Y.; et al.
Prognostic significance of the combined score of endothelial expression of nucleolin and CD31 in surgically
resected non-small cell lung cancer. PLoS ONE 2013, 8, e54674. [CrossRef] [PubMed]
19. Kumar, S.; Gomez, E.C.; Chalabi-Dchar, M.; Rong, C.; Das, S.; Ugrinova, I.; Gaume, X.; Monier, K.;
Mongelard, F.; Bouvet, P. Integrated analysis of mRNA and miRNA expression in HeLa cells expressing low
levels of Nucleolin. Sci. Rep. 2017, 7, 9017. [CrossRef] [PubMed]
20. Gaume, X.; Tassin, A.-M.; Ugrinova, I.; Mongelard, F.; Monier, K.; Bouvet, P. Centrosomal nucleolin is
required for microtubule network organization. Cell Cycle 2015, 14, 902–919. [CrossRef] [PubMed]
21. Bourdon, J.-C.; Khoury, M.P.; Diot, A.; Baker, L.; Fernandes, K.; Aoubala, M.; Quinlan, P.; Purdie, C.A.;
Jordan, L.B.; Prats, A.-C.; et al. p53 mutant breast cancer patients expressing p53γ have as good a prognosis
as wild-type p53 breast cancer patients. Breast Cancer Res. 2011, 13, R7. [CrossRef] [PubMed]
22. Ciriello, G.; Gatza, M.L.; Beck, A.H.; Wilkerson, M.D.; Rhie, S.K.; Pastore, A.; Zhang, H.; McLellan, M.;
Yau, C.; Kandoth, C.; et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell 2015,
163, 506–519. [CrossRef] [PubMed]
23. Maire, V.; Baldeyron, C.; Richardson, M.; Tesson, B.; Vincent-Salomon, A.; Gravier, E.; Marty-Prouvost, B.; De
Koning, L.; Rigaill, G.; Dumont, A.; et al. TTK/hMPS1 is an attractive therapeutic target for triple-negative
breast cancer. PLoS ONE 2013, 8, e63712. [CrossRef] [PubMed]
24. Huang, D.W.; Sherman, B.T.; Lempicki, R.A. Systematic and integrative analysis of large gene lists using
DAVID bioinformatics resources. Nat. Protoc. 2009, 4, 44–57. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
